Nexavar® Evaluated in Locally Recurrent or Metastatic Breast Cancer
According to the results of a Phase II clinical trial, the addition of the targeted therapy Nexavar® (sorafenib) to chemotherapy may delay cancer progression among women with locally recurrent or metastatic, HER2-negative breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Nexavar is a targeted therapy that interferes with several biological pathways associated with the growth of cancer cells. Nexavar has been shown to be effective against liver and kidney cancers, and researchers are exploring its role in the treatment of other types of cancer as well.
To evaluate Nexavar in the treatment of breast cancer, researchers conducted a Phase II clinical trial among women with locally recurrent or metastatic HER2-negative breast cancer. Women were assigned to be treated with paclitaxel chemotherapy alone or in combination with Nexavar.
- Progression-free survival was 6.9 months among women treated with chemotherapy and Nexavar compared with 5.6 months among women treated with chemotherapy alone.
- Women treated with chemotherapy and Nexavar were more likely than women treated with chemotherapy alone to experience serious side effects of treatment.
The results of this study suggest that the addition of Nexavar to chemotherapy may delay cancer progression among women with locally recurrent or metastatic, HER2-negative breast cancer. Because of the frequency of serious side effects, however, it may be important to evaluate lower doses of the drug.
Reference: Gradishar W. A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer. Presented at the 32nd CTRC-AACR San Antonio Breast Cancer Symposium. December 9-13, 2009. San Antonio, TX. Abstract 44.